Tatva Chintan Pharma Chem Limited — Board Meeting, 24-07-2025: Outcome of Board Meeting

Tatva Chintan Pharma Chem's board approved the consolidated financial results for the quarter ended June 30, 2025. Revenue from operations was ₹116.86 Cr, and profit after tax stood at ₹6.65 Cr. Key leadership updates include the re-appointment of Mr. Chintan Nitinkumar Shah as MD and two Whole-time Directors (Mr. Ajaykumar Patel, Mr. Shekhar Somani) for one-year terms. Three Independent Directors (Mr. Subhash Patel, Mr. Manher Desai, Mrs. Avani Umatt) were also re-appointed for five years, pending shareholder approval. Further, Mr. Ashok Bothra resigned as CFO, effective August 30, 2025.